Novartis wins FDA approval for prostate cancer therapy

May 04, 2022

On Wednesday, the U.S. Food and Drug Administration (FDA) granted the approval for Swiss pharma giant, Novartis (NYSE:NVS) to market its radioligand therapeutic agent Pluvicto as a treatment for certain adult patients with prostate cancer.

According to labeling information announced by the FDA, Pluvicto identified as lutetium Lu 177 vipivotide tetraxetan in generic terms is approved for intravenous use in prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC).

The medication is indicated for patients who have received androgen receptor (AR) pathway inhibition and taxane-based chemotherapy.

The decision was based on results from the Phase III VISION trial in which the treatment which was formerly called 177Lu-PSMA-617 along with standard of care (SOC) improved overall survival in PSMA-positive mCRPC patients compared to SOC alone.

Novartis (NVS) added Pluvicto to its pipeline as part of its 2018 acquisition of U.S.-based cancer drugmaker, Endocyte.

Over the current book year the total revenue will be 53.04 billion CHF (consensus estimates). This is slightly more than 2021's revenue of 52.88 billion CHF.

Historical revenues and results Novartis plus estimates 2021

The analysts expect for 2022 a net profit of 13.3 billion CHF. For this year the consensus of the result per share is a profit of 6.21 CHF. The PE-ratio therefore is 13.82.

Huge dividend Novartis

Analysts expect a dividend of 3.36 CHF per share. Thus the dividend yield equals 3.91 percent. The average dividend yield of the pharmaceutical companies equals a limited 1.37 percent.

Novartis 's market capitalization is based on the number of outstanding shares around 193.75 billion CHF. 15

At 17.37 the stock trades 0.63 percent lower at 85.85 CHF.

Historical stock prices Novartis2010-2022

ValueSpectrum.com News Wire & Equity Research: +31 084-0032-842
news@valuespectrum.com

Copyright analist.nl B.V.
All rights reserved. Any redistribution, duplication or archiving prohibited. analist.nl doesn't warrant the accuracy of any News Content provided and shall not be liable for any errors, inaccuracies or for any actions taken in reliance thereon.

Other stock news

Novartis among highest Swiss dividend stocks

Extreme dividend yield Novartis

Novartis now in top highest dividend yields in Switzerland

Novartis expands optogenetics portfolio with acquisition of Arctos Medical

Novartis ends Wet AMD trial for Beovu citing safety concerns

Analysts expect revenue increase Novartis, huge dividend

Extreme dividend yield Novartis

Sector news

Sanofi-Aventis in top French dividend returns

Novartis among highest Swiss dividend stocks

Analysts expect over 2023 revenue increase UCB

Pfizer CEO Bourla says company prepared if modified COVID vaccine required

Analysts: this year best year ever for Carl Zeiss Meditec

Sanofi-Aventis now in top highest dividend yields in France

Extreme dividend yield Novartis

National news

Analysts: less sales Sonova

Analysts expect over 2024 revenue increase Adecco, quite high dividend

Clariant among highest Swiss dividend stocks

Novartis among highest Swiss dividend stocks

Analysts expect over 2023 rising revenue ABB

Adecco in top Swiss dividend returns

Nestle among highest dividend stocks in Switzerland

Press news

ACADIA HEALTHCARE COMPANY, INC. ANNOUNCEMENT: If You Have Suffered Losses in Acadia Healthcare Company, Inc. (NASDAQ: ACHC), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

ROSEN, A LEADING LAW FIRM, Encourages WEBTOON Entertainment Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – WBTN

Momcozy Launches Brand Day Campaign: Empowering Mothers with Comfort and Community

American Airlines ALERT: Bragar Eagel & Squire, P.C. is Investigating American Airlines Group Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C. Is Investigating MaxLinear, Customers Bancorp, Globus, and Metagenomi and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C. Is Investigating Aviat and Flux and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C. Is Investigating Dyne, Napco, and Franklin and Encourages Investors to Contact the Firm

About us	Network	Partners
Fpgroup.nlinfo@analist.nlRSS feedContactIntellectual Property Photos	Analist.nlLinksISIN Glossary	MorningstarPrudena.comAAII.comNASDAQvwd GroupEuronextBATS Chi-x